Invitrogen has announced the launch of the Gibco Opticho protein express kit for serum-free development of stable cell lines for biotherapeutic development.
The kit provides cells banked under cGMP conditions, enabling biotherapeutics manufacturers to speed regulatory submissions and time-to-market.
The Gibco Opticho protein express kit enables biotherapeutics manufacturers to develop stable cell lines where proteins of therapeutic interest can be expressed and reproduced.
It incorporates all of the reagents, protocols and documentation required to go from gene to stable cell clones expressing the protein of interest within a completely serum-free process.
All of the products within the workflow are animal-origin free, which supports the ability to enhance the safety of human therapeutics.
The Opticho kit is available for research use; however, laboratories interested in pursuing regulatory filings that are in need of a documentation package, can purchase a commercial-use licence for a one-off fee, with no maintenance costs or royalties required.
The Opticho protein expression kit can be used as part of a complete workflow for stable cell line development that can be enhanced with use of the Countess automated cell counter to simplify the cell counting steps of the protocol.
Optimised components within the kit, such as Topo TA cloning kits enable faster, more efficient creation of vectors and Freestyle Max Transfection Reagents provide efficient, animal origin-free lipid transfection.
